Related Experiment Video
Updated: Jul 21, 2025
A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
Published on: June 8, 2018
When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?
Matteo Marasco1, Domenico Galasso2, Alberto Larghi3
1Digestive Diseases Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Via di Grottarossa 1035, 00189 Rome, Italy.
Abstract:
Pancreatic neuroendocrine neoplasms (PanNENs) are rare and heterogeneous diseases that account for less than 2% of all cases of pancreatic cancer and only 30% of digestive neuroendocrine neoplasia, even if their incidence and prevalence continue to rise globally [...].
Insights
Pancreatic neuroendocrine neoplasms (PanNENs) are rare but rising cancers. Understanding their characteristics is crucial for improving patient outcomes and treatment strategies for this complex disease.
Area of Science:
- Oncology
- Gastroenterology
- Endocrinology
Background:
- Pancreatic neuroendocrine neoplasms (PanNENs) represent a rare and diverse group of tumors, constituting less than 2% of pancreatic cancers.
- Despite their rarity, the incidence and prevalence of PanNENs are increasing globally, highlighting a growing public health concern.
- PanNENs account for 30% of all neuroendocrine neoplasms originating in the digestive system.
